Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This research is being done to assess the therapeutic activity of a promising combination
(azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible
patients with acute myeloid leukemia.
This study involves the following:
- Venetoclax and azacitidine (investigational combination)
- Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal
daunorubicin and cytarabine (per standard of care)